Acknowledgements
Cancer
MARION, MAY, CANCER
The authors thank all patients and their families. We thank the Institut Jules Bordet as Sponsor of the study. SYNERGY was designed by the authors in collaboration with the Sponsor. This study was conducted with support from AstraZeneca/MedImmune, which provided the study drugs (durvalumab, oleclumab) and a funding contribution for the trial. None of the funders had any role in the study design, data collection, data analysis, data interpretation, or writing of the report. All authors agreed and share the final responsibility for the provided interpretation of the study results and for the decision to submit for publication. We thank all medical staff from the participating sites. We thank CTSU from Institut Jules Bordet for every step of support in the development and conduct of the trial and the previous fellow from the Academic Trials Promoting Team, Mariana Brandao. We are grateful to the BCTL team of the Institut Jules Bordet for the central bio-banking of all biological samples and for helping in the conduct of translational analyses. Thanks, in particular to Delphine Vincent, Alfonsa Laragione, Mathilde Yernaux, Marion Maetens. Thanks to the Center for Cancer Immunotherapy, Institut Curie, Paris, France, and in particular Christina Metoikidou and the Laboratory for Translational Genetics, Department of Human Genetics, VIB Center for Cancer Biology, KU Leuven, Leuven, Belgium and in particular Diether Lambrechts for their collaboration in the translational research. The IDMC committee who reviewed in May 2021 the interim analysis. We thank the MCCR Workshop Faculty for assistance in the protocol development during its attendance by Christian Maurer (2017 session). We are also grateful to the Association Jules Bordet and to the Fondation contre le Cancer for supporting the associated translational research projects.